{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T10:54:54Z","timestamp":1776941694724,"version":"3.51.4"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T00:00:00Z","timestamp":1686528000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To examine the consistency of plasma aldosterone concentration at 1 and 2\u00a0h in the captopril challenge test (CCT) and to explore the possibility of replacing 2-h aldosterone concentration with 1-h aldosterone concentration for diagnosis of primary aldosteronism (PA).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This retrospective analysis included a total of 204 hypertensive patients suspected of having PA. Subjects received oral captopril challenge at 50 mg (25 mg if the systolic blood pressure was &amp;lt;120 mmHg), and plasma aldosterone concentration and direct renin concentration were measured at 1 and 2\u00a0h afterward (chemiluminescence immunoassay Liaison\u00ae DiaSorin, Italy). Sensitivity and specificity were used to reflect the diagnostic performance of 1-h aldosterone concentration using 2-h aldosterone concentration (11 ng\/dl as the cutoff) as the reference. A receiver operating characteristic curve analysis was also conducted.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among the 204 included patients [median age of 57.0 (48.0\u201361.0) years, 54.4% men], a diagnosis of PA was established in 94 patients. Aldosterone concentration in the patients with essential hypertension was 8.40 (interquartile range 7.05\u201311.00) ng\/dl at 1\u00a0h and 7.65 (5.98\u20139.30) ng\/dl at 2\u00a0h (<jats:italic>P<\/jats:italic> &amp;lt; 0.001). In patients with PA, aldosterone concentration was 16.80 (12.58\u201320.50) ng\/dl at 1\u00a0h and 15.55 (12.60\u201320.85) ng\/dl at 2\u00a0h (<jats:italic>P<\/jats:italic> &amp;gt; 0.999). At a cutoff of 11 ng\/dl, the sensitivity and specificity of using 1-h aldosterone concentration to diagnose PA were 87.2% and 78.2%, respectively. A higher cutoff of 12.5 ng\/ml increased specificity to 90.0% but decreased sensitivity to 75.5%. A lower cutoff of 9.3 ng\/ml increased sensitivity to 97.9% but decreased specificity to 65.4%.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>When diagnosing PA with CCT, 1-h aldosterone concentration could not be used to replace 2-h aldosterone concentration.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2023.1183161","type":"journal-article","created":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T04:37:43Z","timestamp":1686544663000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Captopril challenge test in the diagnosis of primary aldosteronism: consistency between 1- and 2-\u00a0h sampling"],"prefix":"10.3389","volume":"14","author":[{"given":"Xinyu","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Bian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sufang","family":"Hao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Lou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huimin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianliang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjun","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,6,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa282","article-title":"Development and validation of criteria for sparing confirmatory tests in diagnosing primary aldosteronism","volume":"105","author":"Wang","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2020.02.052","article-title":"Primary aldosteronism in patients in China with recently detected hypertension","volume":"75","author":"Xu","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa812","article-title":"Significance of discordant results between confirmatory tests in diagnosis of primary aldosteronism","volume":"106","author":"Fukumoto","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-8587(17)30367-4","article-title":"Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study","volume":"6","author":"Hundemer","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-4061","article-title":"The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline","volume":"101","author":"Funder","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1097\/hjh.0000000000002510","article-title":"Genetics, prevalence, screening and confirmation of primary aldosteronism: a position statement and consensus of the working group on endocrine hypertension of the European society of hypertension","volume":"38","author":"Mulatero","year":"2020","journal-title":"J Hypertens"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1177\/1470320320972032","article-title":"The value of the post-captopril Aldosterone\/Renin ratio for the diagnosis of primary aldosteronism and the influential factors: a meta-analysis","volume":"21","author":"Xiang","year":"2020","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1161\/hypertensionaha.117.10197","article-title":"Confirmatory tests for the diagnosis of primary aldosteronism: a prospective diagnostic accuracy study","volume":"71","author":"Song","year":"2018","journal-title":"Hypertension"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2017-01530","article-title":"Evaluation of the saline infusion test and the captopril challenge test in Chinese patients with primary aldosteronism","volume":"103","author":"Meng","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/cen.13943","article-title":"Confirmatory tests for the diagnosis of primary aldosteronism: a systematic review and meta-analysis","volume":"90","author":"Wu","year":"2019","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.109.139832","article-title":"Within-patient reproducibility of the aldosterone: renin ratio in primary aldosteronism","volume":"55","author":"Rossi","year":"2010","journal-title":"Hypertension"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.EJ19-0498","article-title":"Parameters of captopril challenge test can predict results of other confirmatory tests for primary aldosteronism and propose the next test to be done","volume":"67","author":"Tamura","year":"2020","journal-title":"Endocr J"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijchy.2020.100029","article-title":"The 2020 Italian society of arterial hypertension (Siia) practical guidelines for the management of primary aldosteronism","volume":"5","author":"Rossi","year":"2020","journal-title":"Int J Cardiol Hypertens"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.EJ21-0508","article-title":"Japan Endocrine society clinical practice guideline for the diagnosis and management of primary aldosteronism 2021","volume":"69","author":"Naruse","year":"2022","journal-title":"Endocr J"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.16439\/j.issn.1673-7245.2021.11.003","article-title":"Expert consensus on diagnosis and management of primary aldosteronism (2020)","volume":"36","year":"2020","journal-title":"Chin J Endocrinol Metal"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1515\/cclm-2015-1094","article-title":"Prospective validation of an automated chemiluminescence-based assay of renin and aldosterone for the work-up of arterial hypertension","volume":"54","author":"Rossi","year":"2016","journal-title":"Clin Chem Lab Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3803\/EnM.2016.31.2.277","article-title":"Diagnostic role of captopril challenge test in Korean subjects with high aldosterone-to-Renin ratios","volume":"31","author":"Kim","year":"2016","journal-title":"Endocrinol Metab (Seoul)"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1000-3614.2022.07.013","article-title":"Value of plasma aldosterone concentration measure at different time points in captopril challenge test in the diagnosis of primary aldosteronism","volume":"37","author":"Guo","year":"2022","journal-title":"Chin Circ J"},{"key":"B19","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s12902-019-0390-3","article-title":"The captopril challenge test for diagnosing primary aldosteronism in a Chinese population","volume":"19","author":"Zhu","year":"2019","journal-title":"BMC Endocr Disord"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-198814040-00002","article-title":"Pharmacokinetics of captopril in healthy subjects and in patients with cardiovascular diseases","volume":"14","author":"Duchin","year":"1988","journal-title":"Clin Pharmacokinet"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1183161\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T04:37:56Z","timestamp":1686544676000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1183161\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,12]]},"references-count":20,"alternative-id":["10.3389\/fendo.2023.1183161"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2023.1183161","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,12]]},"article-number":"1183161"}}